Avalon Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Avalon Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.93M	Buy	+18,523	New	+$2.5M	0.69%	28
2023 Q3	–	Sell	-54,500	Closed	-$4.53M	–	73
2023 Q2	$4.53M	Buy	54,500 +427	+0.8%	+$35.7K	2.12%	19
2023 Q1	$4.12M	Sell	54,073 -1,117	-2%	-$92.7K	2.11%	17
2022 Q4	$4.58M	Buy	55,190 +113	+0.2%	+$9.15K	2.31%	14
2022 Q3	$4.37M	Sell	55,077 -1,086	-2%	-$91.6K	2.09%	14
2022 Q2	$4.17M	Buy	+56,163	New	+$4.22M	1.71%	16
2018 Q4	–	Sell	-57,740	Closed	-$5.54M	–	60
2018 Q3	$5.54M	Buy	57,740 +37,116	+180%	+$3.6M	5.06%	6
2018 Q2	$1.96M	Buy	20,624 +2,109	+11%	+$194K	1.95%	18
2018 Q1	$1.62M	Sell	18,515 -17,665	-49%	-$1.61M	1.6%	19
2017 Q4	$3.07M	Sell	36,180 -13,415	-27%	-$1.12M	2.74%	8
2017 Q3	$4.29M	Buy	49,595 +10,964	+28%	+$879K	2.97%	4
2017 Q2	$2.98M	Buy	38,631 +13,170	+52%	+$934K	2.2%	14
2017 Q1	$1.76M	Buy	25,461 +21,056	+478%	+$1.41M	1.22%	31
2016 Q4	$261K	Sell	4,405 -26,464	-86%	-$1.63M	0.2%	71
2016 Q3	$2.05M	Buy	+30,869	New	+$1.91M	1.57%	21
2015 Q3	–	Sell	-14,730	Closed	-$1.24M	–	87
2015 Q2	$1.24M	Sell	14,730 -16,875	-53%	-$1.31M	1.13%	38
2015 Q1	$2.38M	Sell	31,605 -31,701	-50%	-$2.21M	1.92%	22
2014 Q4	$3.94M	Buy	+63,306	New	+$3.61M	3.03%	8
2014 Q2	–	Sell	-8,262	Closed	-$392K	–	117
2014 Q1	$392K	Buy	+8,262	New	+$423K	0.32%	81

Other funds holding XBI

MSR

Main Street Research Lakeville, Connecticut $2.12B AUM 67.44% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $188M AUM

Whittier Trust South Pasadena, California $10.2B AUM 33.39% 1-Year Est. Return

AAS

Annex Advisory Services Brookfield, Wisconsin $5.86B AUM 21.83% 1-Year Est. Return

WAM

Weatherly Asset Management Del Mar, California $1.4B AUM 36.32% 1-Year Est. Return

RFM

Royal Fund Management Lady Lake, Florida $1.2B AUM 32.21% 1-Year Est. Return

NHFG

New Harbor Financial Group Worcester, Massachusetts $633M AUM 37.53% 1-Year Est. Return

RAM

Riggs Asset Management Dallas, Pennsylvania $560M AUM 64.94% 1-Year Est. Return

MFS

Madrona Financial Services Everett, Washington $543M AUM 30.87% 1-Year Est. Return

LRPA

L. Roy Papp & Associates Phoenix, Arizona $951M AUM 29.05% 1-Year Est. Return

Avalon Capital Management's XBI Position: Q2 2026 in Review

Avalon Capital Management opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q2 2026: 18,523 shares worth $2.93M. The stake represents 0.69% of the portfolio and ranks #28 among its holdings. This is a return to the name: Avalon Capital Management previously reported a position in XBI as recently as Q2 2023.

Avalon Capital Management first reported a position in XBI in Q1 2014 and has held it in 19 quarters since. The position peaked at $5.54M in Q3 2018. 349 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Avalon Capital Management held 18,523 shares of State Street SPDR S&P Biotech ETF worth $2.93M as of Q2 2026.
State Street SPDR S&P Biotech ETF was a new Avalon Capital Management position in Q2 2026.
State Street SPDR S&P Biotech ETF made up 0.69% of Avalon Capital Management's portfolio in Q2 2026, its #28 holding.
Avalon Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2014 and has held it in 19 quarters since.
Avalon Capital Management's State Street SPDR S&P Biotech ETF position peaked at $5.54M in Q3 2018.
349 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Avalon Capital Management's 13F filing for Q2 2026, filed 16 Jul 2026.